Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,448,761
  • Shares Outstanding, K 301,767
  • Annual Sales, $ 853,830 K
  • Annual Income, $ 690,070 K
  • 60-Month Beta 1.99
  • Price/Sales 7.47
  • Price/Cash Flow 13.93
  • Price/Book 4.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.25
  • Number of Estimates 5
  • High Estimate 0.33
  • Low Estimate 0.19
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.88 +10.06%
on 05/31/19
21.69 -4.20%
on 06/21/19
+0.42 (+2.06%)
since 05/24/19
3-Month
18.80 +10.53%
on 05/15/19
25.20 -17.54%
on 04/03/19
-2.44 (-10.51%)
since 03/22/19
52-Week
13.42 +54.84%
on 10/29/18
25.31 -17.90%
on 03/18/19
+0.74 (+3.69%)
since 06/22/18

Most Recent Stories

More News
Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EXEL : 20.62 (-3.51%)
Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics

The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.

MSFT : 137.74 (+0.56%)
JPM : 109.12 (-0.29%)
JNJ : 143.22 (+0.80%)
MRK : 85.69 (+1.32%)
EXEL : 20.62 (-3.51%)
HD : 205.44 (-1.89%)
BA : 374.67 (+0.76%)
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.

MRK : 85.69 (+1.32%)
LLY : 116.00 (+0.44%)
EXEL : 20.62 (-3.51%)
BMY : 45.67 (-7.44%)
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

--I Exelixis will make upfront payment and contribute research funding for option to in-license at Investigational New Drug (IND) filing I

EXEL : 20.62 (-3.51%)
Exelixis Inc Shares Down 12.9% Since SmarTrend's Sell Call (EXEL)

SmarTrend identified a Downtrend for Exelixis Inc (NASDAQ:EXEL) on April 17th, 2019 at $22.10. In approximately 4 weeks, Exelixis Inc has returned 12.92% as of today's recent price of $19.24.

EXEL : 20.62 (-3.51%)
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.

MRK : 85.69 (+1.32%)
EXEL : 20.62 (-3.51%)
PFE : 43.79 (+0.27%)
BMY : 45.67 (-7.44%)
Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019

Exelixis, Inc.(Nasdaq: EXEL) today announced thatthe company will be presenting at the following two investor conferences on Tuesday, May 21, 2019, in New York:

EXEL : 20.62 (-3.51%)
Exelixis' Collaborator Daiichi Sankyo Launches MINNEBRO(R) (Esaxerenone) Tablets in Japan

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited ("Daiichi Sankyo") has launched MINNEBRO(R) (esaxerenone) tablets as a treatment for patients with...

EXEL : 20.62 (-3.51%)
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1

Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.

EXEL : 20.62 (-3.51%)
RHHBY : 35.4000 (-0.56%)
PFE : 43.79 (+0.27%)
BMY : 45.67 (-7.44%)
Exelixis (EXEL) Beats Q1 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 12.50% and 5.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

EXEL : 20.62 (-3.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade EXEL with:

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 22.17
1st Resistance Point 21.77
Last Price 20.62
1st Support Level 20.89
2nd Support Level 20.41

See More

52-Week High 25.31
Fibonacci 61.8% 20.77
Last Price 20.62
Fibonacci 50% 19.36
Fibonacci 38.2% 17.96
52-Week Low 13.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar